CIK 1121404
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 100.00% | 9 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | MGTX | MeiraGTx Holdings plc | Health Care | 31.44% |
| 2 | INBX | Inhibrx Biosciences, Inc. | Health Care | 23.17% |
| 3 | NVAX | NOVAVAX INC | Health Care | 16.67% |
| 4 | ANAB | ANAPTYSBIO, INC | Health Care | 9.04% |
| 5 | AGMB | Agomab Therapeutics NV | Health Care | 8.69% |
| 6 | MPLT | MapLight Therapeutics, Inc. | Health Care | 5.52% |
| 7 | IMRX | Immuneering Corp | Health Care | 4.25% |
| 8 | ELDN | Eledon Pharmaceuticals, Inc. | Health Care | 0.75% |
| 9 | QTTB | Q32 Bio Inc. | Health Care | 0.47% |
9/9 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 91.3%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 17% of book weight classified — the grid is NOT representative of the whole book.
Classified: 17.1% of book weight (2/9 names) · unclassified 82.9%: MGTX, INBX, ANAB, AGMB, MPLT, IMRX, ELDN. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | MGTXMEIRAGTX HLDGS PLC | 12,197,737 | $106M | 31.4% | HOLD |
| 2 | INBXINHIBRX BIOSCIENCES INC | 1,157,926 | $78M | 23.2% | HOLD |
| 3 | NVAXNOVAVAX INC | 6,880,481 | $56M | 16.7% | HOLD |
| 4 | ANABANAPTYSBIO INC | 821,917 | $30M | 9.0% | HOLD |
| 5 | AGMBAGOMAB THERAPEUTICS NV | 2,783,096 | $29M | 8.7% | NEW |
| 6 | MPLTMAPLIGHT THERAPEUTICS INC | 912,041 | $19M | 5.5% | HOLD |
| 7 | IMRXIMMUNEERING CORP | 2,708,559 | $14M | 4.2% | HOLD |
| 8 | ELDNELEDON PHARMACEUTICALS INC | 814,980 | $3M | 0.7% | HOLD |
| 9 | QTTBQ32 BIO INC | 244,083 | $2M | 0.5% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| MGTXMEIRAGTX HLDGS PLC | 12.2M | 12.2M | 12.2M | 12.2M | 12.2M | 12.2M | $106M |
| INBXINHIBRX BIOSCIENCES INC | 1.2M | 1.2M | 1.2M | 1.2M | 1.2M | 1.2M | $78M |
| NVAXNOVAVAX INC | 6.9M | 6.9M | 6.9M | 6.9M | 6.9M | 6.9M | $56M |
| ANABANAPTYSBIO INC | 822K | 822K | 822K | 822K | 822K | 822K | $30M |
| AGMBAGOMAB THERAPEUTICS NV | — | — | — | — | — | 2.8M | $29M |
| MPLTMAPLIGHT THERAPEUTICS INC | — | — | — | — | 912K | 912K | $19M |
| IMRXIMMUNEERING CORP | — | — | — | 2.7M | 2.7M | 2.7M | $14M |
| ELDNELEDON PHARMACEUTICALS INC | 815K | 815K | 815K | 815K | 815K | 815K | $3M |
| QTTBQ32 BIO INC | 244K | 244K | 244K | 244K | 244K | 244K | $2M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
